Rachel H. Giles, PhD, and Kirk Knowlton, MD, discuss the results from the VICTORION-INCEPTION Trial presented at the National Lipid Association, highlighting how early use of inclisiran in high-risk post-myocardial infarction patients significantly improved LDL cholesterol control compared to usual care, offering a practical solution for those struggling to reach lipid targets despite maximally tolerated statin therapy.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Physician’s Weekly, their employees, and affiliates.
Create Post
Twitter/X Preview
Logout